Taxanes in breast cancer: An update

被引：41

作者：

Conlin A.K. ^{[1
]}

Seidman A.D. ^{[1
]}

机构：

[1] Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

来源：

Current Oncology Reports | 2007年 / 9卷 / 1期

关键词：

Bevacizumab; Metastatic Breast Cancer; Onse Rate; North American Breast;

D O I：

10.1007/BF02951422

中图分类号：

学科分类号：

摘要：

Over the past decade the taxanes have proved to be fundamental in the treatment of breast cancer, Initially found to have efficacy in metastatic breast cancer, the taxanes are now vital components in the treatment of early-stage disease, in which their addition to adjuvant treatment of early breast cancer has been shown to improve overall survival. In addition, the taxanes have demonstrated a role in first-line therapy for metastatic disease, with some of the highest efficacy of any class of chemotherapy. Targeted therapies in combination with the taxanes have further improved survival for both early and metastatic disease. New formulations of taxanes may both improve antitumor activity and reduce toxicity. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：22 / 30

页数：8

共 54 条

[1]

Seidman A.D., Tiersten A., Hudis C., Et al., Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer, J Clin Oncol, 13, pp. 2575-2581, (1995)

[2]

Chan S., Friedrichs K., Noel D., Et al., Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, J Clin Oncol, 17, (1999)

[3]

Sledge Jr. G.W., Neuberg D., Bernardo P., Et al., Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193), J Clin Oncol, 21, pp. 588-592, (2003)

[4]

Bishop J.F., Denwar J., Toner G.C., Et al., Initial paclitaxel improves outcome compared to CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer, J Clin Oncol, 17, pp. 2355-2364, (1999)

[5]

Mamounas E.P., Bryant J., Lembersky B., Et al., Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28, J Clin Oncol, 23, pp. 3686-3696, (2005)

[6]

Henderson I.C., Berry D.A., Demetri G.D., Et al., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J Clin Oncol, 21, pp. 976-983, (2003)

[7]

Martin M., Pienkowski T., Macky J., Et al., Adjuvant docetaxel for node-positive breast cancer, N Engl J Med, 352, pp. 2302-2313, (2005)

[8]

Jones S.E., Savin M.A., Holmes F.A., Et al., Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin /cyclophosphamide) in 1016 women with early stage breast cancer. Presented at the San Antonio Breast Cancer Symposium, (2005)

[9]

Bear H.D., Anderson S., Smith R.E., Et al., Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B027, J Clin Oncol, 24, pp. 2019-2027, (2006)

[10]

Roche H., Fumoleau P., Spielman M., Et al., Five years analysis of the PAC01 trial: 6 cycles of FEC 100 versus 3 cycles of FEC 100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer, Breast Cancer Res Treat, 88, SUPPL. 1, (2004)

← 1 2 3 4 5 6 →